November 15, 2024

Detecting Evidence of Lung Cancer in Exhaled Breath

Researchers may have developed ultrasensitive, nanoscale sensors that distinguished a key change in the chemistry of the breath of patients with lung cancer.

The ASCO Post

November 08, 2024

Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC

An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the ne...

The ASCO Post

November 08, 2024

Tarlatamab-dlle for Previously Treated Extensive-Stage SCLC

On May 16, 2024, tarlatamab-dlle (Imdelltra) was granted accelerated approval for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Tarlat...

The ASCO Post

November 08, 2024

Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024

At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and...

The ASCO Post

November 05, 2024

$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities

Researchers were awarded a $2.5 million grant from the Bristol Myers Squibb Foundation to establish a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.

The ASCO Post

October 30, 2024

Lung Cancer Screening Model May Remove Barriers for Vulnerable Patients Residing in Central Texas

Researchers have examined whether a new lung cancer screening initiative could help overcome barriers to care among low-income, uninsured, and minority patients residing in Central Texas.

The ASCO Post

October 24, 2024

Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC

The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line ...

The ASCO Post

October 23, 2024

Preoperative Chemotherapy and Perioperative Nivolumab in NSCLC

As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with s...

The ASCO Post

January 12, 2024

Changing Medical Practice Through Translational Research Successes

Converting data and science into medical progress requires a strategic emphasis on work that matters to patients, either through imminent application to clinical practice or potentially transformative basic discoveries.

Cedars-Sinai Pulse